2018
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting. JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDNA, NeoplasmFemaleGenes, erbB-1GenomicsGenotypeHumansImmunotherapyLung NeoplasmsMaleMiddle AgedMutationNeoplasm StagingReceptor Protein-Tyrosine KinasesRetrospective StudiesSequence Analysis, DNASurvival AnalysisConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCommunity oncology settingCell lung cancerLung cancerOncology settingRoutine testingNonsquamous non-small cell lung cancerTargeted treatmentPropensity score-matched survival analysisStage IIIB/IVFlatiron Health databaseIIIB/IVRetrospective cohort studyThird-line treatmentFirst-line treatmentMinority of patientsUnadjusted mortality ratesEGFR/ALKCohort studyOverall survivalSecondary outcomesUnmatched cohortPrimary outcomeAntineoplastic treatment
2013
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma
Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathology 2013, 121: 500-507. PMID: 23495083, DOI: 10.1002/cncy.21288.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseBiomarkers, TumorBone NeoplasmsCytodiagnosisDNA, NeoplasmErbB ReceptorsFeasibility StudiesFemaleGene RearrangementHumansIn Situ Hybridization, FluorescenceLiver NeoplasmsLung NeoplasmsMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesSoft Tissue NeoplasmsYoung AdultConceptsALK gene rearrangementMetastatic lung adenocarcinomaEGFR mutationsKRAS mutationsMetastatic tumorsEpidermal growth factor receptorLung adenocarcinomaCytological specimensGene rearrangementsMolecular testsMolecular alterationsKirsten rat sarcoma viral oncogene homolog (KRAS) mutationsALK gene rearrangement analysisAnaplastic lymphoma kinase (ALK) gene rearrangementEGFR T790M mutationRat sarcoma viral oncogene homolog mutationsCases of lungT790M mutationImportant therapeutic implicationsFine needle aspiratesGene rearrangement analysisCell block materialGrowth factor receptorRecurrent lungRecurrent adenocarcinoma
2002
Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results
Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002, 37: 17-27. PMID: 12057863, DOI: 10.1016/s0169-5002(02)00035-1.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerHER2 overexpressionClinical trialsHER2-overexpressing metastatic breast cancerAntibody-dependent cell-mediated cytotoxicityMetastatic breast cancer trialsRandomized phase II trialRecombinant humanized monoclonal antibodyActivity of trastuzumabNSCLC clinical specimensPhase II studyPhase II trialEfficacy of trastuzumabMetastatic breast cancerBreast cancer trialsCell lung cancerCell-mediated cytotoxicityPoor clinical outcomeTreatment of patientsLung cancer clinical trialsHumanized monoclonal antibodyCombination of chemotherapyOverexpression of HER2Cancer clinical trialsDownregulation of HER2